<!DOCTYPE html>
<html>

<head>
	<meta charset="UTF-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link href="/index.css" type="text/css" rel="stylesheet">
	<script src="//code.jquery.com/jquery-1.10.2.js"></script>
	<script>
		$(function () {
			$("header").load("/header.html");
			$("footer").load("/footer.html");
		});
	</script>
	<script>
		function navDrop() {
			var x = document.getElementById('navlinks');
			if (x.style.display === 'flex') {
				x.style.display = 'none';
			} else {
				x.style.display = 'flex';
			}
		}
	</script>
</head>

<body>
	<header></header>
	<div class="spacer"></div>
	<div class="main">
		<h1 id="cellulitis-syndromes">Cellulitis Syndromes</h1>
		<h2 id="postvascular-surgery-cellulitis">Post–vascular Surgery Cellulitis</h2>
		<h3 id="etiology-9">Etiology</h3>
		<p>The most significant aspect of post-surgical infections is that many patients have vascular grafts placed.
		</p>
		<h3 id="microorganisms-3">Microorganisms</h3>
		<p>Most common:</p>
		<ul>
			<li>Coag-negative Staphylococcus</li>
			<li><em>Staphylococcus aureus</em></li>
		</ul>
		<p>Others:</p>
		<ul>
			<li>Non-tuberculosis mycobacteria</li>
			<li>Nocardia species</li>
			<li>Legionella species</li>
			<li>Mycoplasma species</li>
			<li>Cutibacterium species</li>
		</ul>
		<h3 id="inguinal">Inguinal</h3>
		<h4 id="epidemiology-4">Epidemiology</h4>
		<p>Abdominal aortic aneurysm repair and endovascular techniques are associated with the lowest rates of SSI
			(&lt;1%).</p>
		<p>Infrainguinal open bypass procedures show the highest rates (10–30%).</p>
		<h4 id="etiology-10">Etiology</h4>
		<p>In vascular surgery, SSTI is reported to occur in 5–10% of patients.</p>
		<p>Gram-positive organisms are the most common pathogens, causing up to 80% of vascular SSTI. Most frequently:
		</p>
		<ul>
			<li><em>S. Aureus</em></li>
			<li>Coagulase-negative staphylococci</li>
		</ul>
		<p>About 20–25% of vascular SSTIs are attributable to Gram-negative bacteria. Most frequently:</p>
		<ul>
			<li><em>Escherichia coli</em></li>
			<li><em>Pseudomonas aeruginosa</em></li>
			<li>Proteus ssp.</li>
			<li><em>Klebsiella pneumoniae</em></li>
		</ul>
		<p>Antibiotic-resistant organisms are increasingly responsible for SSTI</p>
		<ul>
			<li>Many studies now report MRSA as most common pathogenic organism responsible for SSTI</li>
		</ul>
		<hr/>
		<figure>
			<img src="/figures/vgi-presentation.png">
			<figcaption><strong>Figure 1.</strong> Extracavitary vascular graft infection: diagnosis using Samson classification. CT indicates computed tomography; I&D, irrigation and debridement; and MRI, magnetic resonance imaging.[<a href="#wilson">1</a>]</figcaption>
		</figure>
		<hr/>
		<h4 id="management-7">Management</h4>
		<h5>Empiric parenteral therapy</h5>
		<p>Vancomycin plus cefepime or piperacillin-tazobactam</p>
		<h5>Alternative empiric parenteral therapy</h5>
		<p>Daptomycin or linezolid plus carbapenem</p>
		<p>Definitive therapy should be pathogen-directed if possible and may require the addition of rifampin if a
			foreign body remains and <em>S. aureus</em> is identified.</p>
		<h5 id="extracavitary-vgis-recommendations-for-management-antimicrobial-therapy">Extracavitary VGIs: Recommendations for Management: Antimicrobial Therapy</h5>
				<p><span class="h6">Samson class I or II VGI:</span> a trial of antimicrobial therapy with or without surgical débridement for 2 or 4 weeks is reasonable (<em>Class IIa; Level of Evidence B</em>).</p>
				<p><span class="h6">Samson class III or IV VGI:</span> postoperative antimicrobial therapy for 4 to 6 weeks is reasonable (<em>Class IIa; Level of Evidence B</em>).</p>
				<p></p>After the initial therapy, a course of oral antimicrobial therapy for 6 weeks to 6 months may be considered (<em>Class IIb; Level of Evidence B</em>).</p>
				<p><span class="h6">Samson class V VGI:</span> postoperative antimicrobial therapy for 4 to 6 weeks administered parenterally, followed by at least 6 months of therapy administered orally may be considered (<em>Class IIb; Level of Evidence B</em>).</p>
				<p><span class="h6">Samson class III, IV, or V VGI:</span> long-term suppressive antimicrobial therapy may be considered for:</p>
				<ul>
					<li>Infection caused by</li>
					<ul>
						<li>MRSA</li>
						<li>Pseudomonas</li>
						<li>Multidrug-resistant organisms</li>
						<li>Candida</li>
						<li>Other fungal species</li>
					</ul>
					<li>Patients who</li>
					<ul>
						<li>Have undergone emergency or multiple surgeries</li>
						<li>Have graft preservation or in situ reconstruction with extensive perigraft infection</li>
						<li>Are poor candidates for reoperation</li>
					</ul>
				</ul>
				<p>(<em>Class IIb; Level of Evidence B</em>).</p>
			</li>
		</ol>
		<h5 id="extracavitary-vgis-recommendations-for-management-surgical-therapy">Extracavitary VGIs: Recommendations
			for
			Management: Surgical Therapy</h5>
				<p><span class="h6">Samson class III infection, early (&lt;2 months postoperatively):</span> reasonable to consider graft preservation rather than graft excision and reconstruction (<em>Class IIa; Level of Evidence B</em>).</p>
				<p><span class="h6">Samson class III infection (&lt;2 months postoperatively):</span> graft excision and
					reconstruction may be considered instead of graft preservation (<em>Class IIb; Level of Evidence
						B</em>).
				</p>
				<p><span class="h6">Samson class III or lV infection caused by MRSA, Pseudomonas, or multidrug-resistant
					microorganisms</span> or
					for patients for whom <span class="h6">graft preservation or in situ reconstruction has failed</span>, it is reasonable to perform extra-anatomic revascularization, followed by graft excision instead of graft preservation or in situ reconstruction (<em>Class IIa; Level of Evidence B</em>).</p>
				<p><span class="h6">Samson class V VGI:</span> extra-anatomic revascularization followed by graft excision is reasonable (<em>Class IIa; Level of Evidence B</em>).</p>
				<p><span class="h6">Samson class III, IV, or V VGI:</span> ultrasound examination every 3 to 6 months for 2 years, followed by lifelong ultrasound examination every 6 to 12 months, is reasonable (<em>Class IIa; Level of Evidence B</em>).</p>
		<h3 id="av-shunts">AV shunts</h3>
		<ul>
			<li>
				<p>A permanent vascular access made by using an existing artery and vein</p>
			</li>
			<li>
				<p>Used for long-term hemodialysis</p>
			</li>
		</ul>
		<h4 id="likely-organismsource-2">Likely organism/source</h4>
		<ul>
			<li>
				<p><em>Staphylococcus aureus</em></p>
			</li>
			<li>
				<p><em>Staphylococcus epidermidis</em></p>
			</li>
			<li>
				<p>Patient at high risk of bacteremia during access of AV fistula</p>
			</li>
		</ul>
		<h4 id="risk-factors-for-infection">Risk factors for infection</h4>
		<ul>
			<li>
				<p>Pseudoaneurysm</p>
			</li>
			<li>
				<p>Hematoma</p>
			</li>
			<li>
				<p>Pruritus of shunt</p>
			</li>
			<li>
				<p>Misuse of access (IV drugs)</p>
			</li>
		</ul>
		<h4 id="treatment-8">Treatment</h4>
				<p>IV antibiotics and surgical drainage</p>
				<p>Assess for:</p>
			<ul>
				<li>Fever</li>
				<li>Skin integrity</li>
				<li>Bacteremia with blood cultures</li>
				<li>Fluid culture if abscess present</li>
				<li>Signs of systemic infection</li>
			</ul>
				<p>Although AV fistulas SSTI may not be the source of IE, they nevertheless need to be excluded due to the proximity of endovascular infection.</p>
		<h4 id="empiric-parental-therapy-see-ssti">Empiric parental therapy (See SSTI)</h4>
		<p>Treatment pathogen-directed or empiric for staphylococcus or streptococcus</p>
		<h5 id="parenteral-therapy-1">Parenteral therapy</h5>
				<p><span class="h6">MSSA:</span> Nafcillin, cefazolin, clindamycin</p>
				<p><span class="h6">MRSA:</span> Vancomycin, daptomycin linezolid, clindamycin</p>
		<h5 id="oral-therapy-1">Oral therapy</h5>
				<p><span class="h6">MSSA:</span> Clindamycin, Cephalexin, Trim-sulfa, Doxycycline</p>
				<p><span class="h6">MRSA:</span> Doxycycline, Trim-sulfa</p>
		<!-- <p><a href="https://www-uptodate-com.echo.louisville.edu/contents/arteriovenous-fistula-creation-for-hemodialysis-and-its-complications?search=av%20fistula%20infection&amp;source=search_result&amp;selectedTitle=1\textasciitilde150&amp;usage_type=default&amp;display_rank=1">https://www-uptodate-com.echo.louisville.edu/contents/arteriovenous-fistula-creation-for-hemodialysis-and-its-complications?search=av%20fistula%20infection&amp;source=search_result&amp;selectedTitle=1\textasciitilde150&amp;usage_type=default&amp;display_rank=1</a> </p> -->
		<h3>References</h3>
		<ol>
			<li id="wilson">Wilson WR, Bower TC, Creager MA, Amin-Hanjani S, O'Gara PT, Lockhart PB, Darouiche RO, Ramlawi B, Derdeyn CP, Bolger AF, Levison ME, Taubert KA, Baltimore RS, Baddour LM; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; Council on Peripheral Vascular Disease; and Stroke Council. Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association. Circulation. 2016 Nov 15;134(20):e412-e460. <a href="https://doi.org/10.1161/cir.0000000000000457">doi: 10.1161/CIR.0000000000000457</a>. Epub 2016 Oct 13. <a href="https://pubmed.ncbi.nlm.nih.gov/27737955/">PMID: 27737955</a>.</li>
		</ol>
	</div>
	<footer></footer>
</body>

</html>